Cachexia

11/01/2016 - "Although the studies reviewed here report positive results, there is still little evidence available on the use of ghrelin to treat cachexia. "
11/01/2016 - "Studies were eligible for inclusion if they were conducted in adult patients with a diagnosis of cachexia and provided information on type of ghrelin or analogue used, route of administration and dose administered, duration of intervention, outcomes, and clinical trial study design. "
11/01/2016 - "Use of ghrelin in cachexia syndrome: a systematic review of clinical trials."
05/01/2014 - "Several studies indicate that ghrelin administration is a valid treatment for cachexia because it improves muscle mass and function, likely by restoring a positive energy balance. "
01/01/2013 - "These effects of ghrelin have been confirmed in multiple types of cachexia in both laboratory and human studies, suggesting a positive future for cachexia treatments."

09/01/2018 - "In a recent genome-wide association study, it was shown that placentation, appetite, and the cachexia gene GDF15 are linked to HG. The purpose of this study was to explore whether GDF15 alleles linked to overexpression of GDF15 protein segregate with the condition in families, and whether the GDF15 risk allele is associated with recurrence of HG. Methods We analyzed GDF15 overexpression alleles for segregation with disease using exome-sequencing data from 5 HG families. "
01/01/2017 - "To assess the effect of protein supplementation and exercise on the development of cardiac cachexia, data on various measures of muscle quality, cardiovascular health, mental status, and quality of life were collected and analyzed from the two groups at the beginning and end of the study period. "
11/01/2009 - "Only very few recent randomized controlled trials have studied the effects of protein supplementation in clinical cachexia. "
06/01/2007 - "Our study demonstrates a cachexia-associated loss of Akt-dependent signalling in human skeletal muscle with decreased activity of regulators of protein synthesis and a disinhibition of protein degradation."
05/01/2006 - "Moreover, no study has assessed the relationship of protein turnover to hormonal alterations thought to promote cachexia. "

03/01/2022 - "Clinical trials of anamorelin have demonstrated a significant increase in lean body mass index, improved cachexia and no significant increase in serious adverse events. "
01/01/2020 - "The aim of this study is to examine the efficacy of anamorelin in improving appendicular skeletal muscle mass (ASM) and patient-reported outcomes in patients with MM with cachexia. "
08/01/2017 - "ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and efficacy of anamorelin in advanced NSCLC patients with cachexia. "
05/01/2015 - "In the ROMANA 2 trial, 477 patients with unresectable stage III or IV NSCLC and cachexia were to be enrolled and randomized (2:1) to receive anamorelin HCl or placebo once daily for 12 weeks. "
04/01/2014 - "The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia."

08/01/1999 - "An understanding of the relation between cachexia and negative regulatory cytokines may point to effective treatment of geriatric cachexia as well."
12/01/2008 - "Studies of host cytokine genotype have demonstrated that specific host cytokine polymorphisms are associated with both the development of cachexia and reduced patient survival. "
04/01/2000 - "Data from in vitro studies and animal models suggest that increased levels of inflammatory cytokines can induce cachexia and might inhibit the effects of GH on target tissues. "
09/01/1997 - "These latter type of studies revealed that cachexia can rarely, if ever, be attributed to one single cytokine but rather to a set of cytokines that work in concert in cachexia. "
09/01/1997 - "However, from various studies it has become clear that the action of TNF can only be understood in the context of simultaneous presence of other cytokines, some of which have activities that are at the least equally important as TNF in bringing about cachexia. "

01/01/2011 - "Attenuation of IL-6 signaling was effective in blocking the progression of cachexia, but not sufficient to reverse the process."
05/01/2015 - "Future studies in the female will need to determine mechanisms underlying regulation of IL-6 response and cachexia induction."
05/01/2015 - "The purpose of this study was to examine the relationship between IL-6 signaling and cachexia progression in the female Apc(Min/+) mouse. "
02/08/2023 - "A comparison of the survival curves by Kaplan-Meier analysis showed a significantly lower OS in patients with cachexia versus those without cachexia (p = 0.0323), as well as higher miniCASCO-based cachexia severity (p = 0.0428), an mGPS of 2 versus those with a lower mGPS (p = 0.0074), and higher IL-6 levels (>6 ng/mL) versus those with lower IL-6 levels (≤6 ng/mL) (p = 0.0120). "
02/08/2023 - "As for survival outcomes, multivariate COX regression analysis found that IL-6 levels and miniCASCO-based cachexia severity significantly affected PFS (hazard ratio (HR) = 1.0388; 95%CI = 1.0230-1.0548; p < 0.001 and HR = 1.2587; 95%CI = 1.0850-1.4602; p = 0.0024, respectively) and OS (HR = 1.0404; 95%CI = 1.0221-1.0589; p < 0.0001 and HR = 2.3834; 95%CI = 1.1504-4.9378; p = 0.0194, respectively). "

05/01/1989 - "Nursing interventions to stimulate appetite and promote greater food intake, coupled with the use of agents that alter metabolism, such as megestrol acetate, may reverse the trend of cachexia and thus provide an increased sense of well-being and improved quality of life."
08/01/1998 - "Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia."
01/01/2010 - "Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia."
01/01/2006 - "The aim is to review major clinical trials that have used megestrol acetate (MA) in the treatment of cachexia across several disease states. "
12/01/1990 - "The true effectiveness of megestrol acetate for HIV-related cachexia and the effects of treatment on quality of life are currently being assessed in a national prospective, randomized, double-blind, placebo-controlled trial."

01/01/2010 - "(1) To compare ghrelin receptor expression between clinically stable CF subjects with normal BMI, CF subjects with cachexia and healthy controls. "
01/01/2019 - "The ghrelin receptor [growth hormone secretagogue receptor (GHSR)-1a] represents a promising pharmacologic target for the treatment of metabolic disorders, including obesity and cachexia, via central appetite modulation. "
11/01/2015 - "Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist."
07/01/2022 - "Further research is needed to evaluate the efficacy of the ghrelin receptor agonist for cancer cachexia in pancreatic cancer patients. "
01/01/2017 - "Background and Aims: The ghrelin receptor is one of the new therapeutic targets in the cancer anorexia-cachexia syndrome. "

05/01/1999 - "Several studies have shown that cardiac cachexia is linked to increased plasma levels of tumor necrosis factor alpha. "
03/01/1999 - "Several studies have shown that cardiac cachexia is linked to raised plasma levels of tumor necrosis factor-ac. "
02/01/2015 - "Tumor Necrosis Factor-alpha (TNF-α) contributes to the pathophysiology of CF by causing cachexia. "
12/01/2010 - "TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia?"
02/01/2010 - "These data suggest hypothalamic TNFalpha action to be important mediator of the wastage syndrome in cachexia."

11/01/2023 - "Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia."
05/13/2022 - "Based on this, we designed an MC4R antagonist peptide, TCMCB07, that successfully treated many forms of cachexia. "
05/13/2022 - "Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides."
12/01/2020 - "TCMCB07 is a cyclic nonapeptide peptide MC4R antagonist with parenteral anti-cachexia activity in both small and large animal models. "
11/01/2012 - "Previously, we demonstrated that agouti-related peptide (AgRP), a melenocortin-4 receptor antagonist, reduced CKD-associated cachexia in CKD mice. "

02/13/2020 - "In this context, the use of animal model of cisplatin-induced cachexia is very useful. "
10/01/2022 - "PGC1α overexpression preserves muscle mass and function in cisplatin-induced cachexia."
09/05/2019 - "Moreover, in a model of cisplatin-induced cachexia, GHS protect skeletal muscle from mitochondrial damage and improve lean mass recovery. "
03/01/2015 - "The chemotherapeutic drug cisplatin causes a number of dose-dependent side effects, including cachexia and testicular damage. "
05/01/2014 - "Protective effect of Panax ginseng in cisplatin-induced cachexia in rats."

01/01/2018 - "Most research to date has focused on treating muscle depletion as part of the cachexia syndrome using nutritional, exercise and pharmacological interventions; however, these single-agent therapies have not provided promising results. "
12/01/2016 - "Optimal nutritional therapy remains the mainstay of treatment of cachexia in CKD children with therapeutic goals of maintaining BMI as well as linear growth within the normal range."
07/01/2021 - "Notably, FcRn activity is essential for proper antigen presentation and antitumour immunity, which may permit the study of cachexia's impact on FcRn-mediated clearance and efficacy of ICI therapies."
04/15/2014 - "These data demonstrate that cachexia alters the muscle metabolic response to acute LoFS, and combination therapies in concert with muscle contraction may be beneficial for improving muscle mass and function during cachexia. "
09/20/2013 - "In patients with advanced HF and severe PH, SILD therapy has beneficial effects on hemodynamics, clinical status, cardiac cachexia, and contributes to improved peri-transplant survival."

10/05/2019 - "Also the results showed that simultaneous application of CUPE and Dox leads to significant reduction of cachexia from the Dox chemotherapy."
06/01/2023 - "Chemotherapy-induced cachexia causes severe metabolic abnormalities independently of cancer and reduces the therapeutic efficacy of chemotherapy. "
01/01/2020 - "As there is currently no accepted pharmacotherapy option for cachexia available in the West, a transfer of these East Asian gold standard prescriptions into the European market would be desirable. "
01/01/2023 - "In this study, we developed a fully human GFRAL antagonist antibody and investigated whether it inhibits the GDF15/GFRAL/RET axis, thereby alleviating chemotherapy-induced cachexia in tumour-bearing mice. "
12/01/2021 - "Our study illustrates the importance of REDD1 in the regulation of muscle mass with chemotherapy treatment and may be an attractive therapeutic target to combat cachexia."

02/08/2023 - "Further larger studies are needed to confirm these findings and to explore the potential benefit of counteracting cachexia to improve immunotherapy efficacy."
10/01/2023 - "However, the mechanisms behind the development of cachexia and its prognostic impact on immunotherapy efficacy are not fully understood. "
02/08/2023 - "Herein, we carried out a prospective study aimed at evaluating the prognostic and predictive role of cachexia with the related changes in nutritional, metabolic, and inflammatory parameters (assessed by the multidimensional miniCASCO tool) on the survival and clinical response (i.e., disease control rate) to ICI-based immunotherapy in patients with advanced NSCLC. "
01/01/2023 - "However, the impact of cachexia on immunotherapy, such as PD-1/L1 inhibitors, is not fully understood. "
12/23/2021 - "The cachexia was evaluated before and after the second course of immunotherapy. "

11/01/2006 - "Progressive resistance training and other interventions aimed at stimulating skeletal muscle growth might be beneficial in this population, and further studies on the pathophysiology of cachexia in AS patients are needed."
01/01/2011 - "Although strength-training exercise has been used in persons with RA, it is not clear if it is effective for reducing cachexia. "
06/01/2005 - "A Phase II trial was performed as a preliminary test of the efficacy and safety of progressive resistance training (PRT) as adjunct treatment for rheumatoid cachexia. "
01/01/2011 - "A 46-year-old woman was studied to determine: (i) if resistance exercise could reverse cachexia by improving muscle mass, fiber cross-sectional area, and muscle function; and (2) if elevated apoptotic signaling was involved in cachexia with RA and could be reduced by resistance training. "
08/01/2008 - "Cachexia shows little response to diet alone but progressive resistance training and anti-TNF therapies show promise in tackling this potentially disabling extra-articular feature of RA."

04/01/2022 - "Challenges in parenteral nutrition in adult ultrashort gut: A case of cachexia."
05/01/2021 - "The Patient was admitted into the intensive care unit for severe cachexia and poor general condition 24 after introduction of parenteral nutrition (1500 Kcal/day). "
01/01/2011 - "There was progressive cachexia and parenteral nutrition had to be instituted. "
03/09/2010 - "To examine the impact of additional parenteral nutrition (APN) we assessed outpatients suffering from APC and progressive cachexia. "
12/01/2006 - "Diet supplementation and intradialytic parenteral nutrition have not been successful in reversing cachexia in CKD. "